



TISSUE THERAPIES

21 July 2008

Dear Optionholder

Share Purchase Plan – Optionholders' Participation

Tissue Therapies today announced its Share Purchase Plan (**SPP**), which will provide the opportunity for eligible shareholders to purchase up to \$5,000 of TIS ordinary shares without incurring brokerage or transaction costs.

Investors who hold options in Tissue Therapies but do not hold shares may only participate in the SPP if some or all of their options are exercised prior to the Record Date, being 4 August 2008, and they are recorded on the share register as shareholders.

Shareholders who also hold options will not be entitled to purchase any more than \$5,000 of TIS ordinary shares under the SPP by exercising some or all of their options before the Record Date.

Please contact our share registry should you wish to exercise your options.

The share registry contact details are:

Postal address:

Link Market Services Limited
Locked Bag 3415
BRISBANE QLD 4001

Hand delivery:

Link Market Services Limited
Level 12, 300 Queen Street
BRISBANE QLD 4000

Telephone: 1300 554 474 (within Australia) or +61 2 82807475 (outside Australia)

Yours sincerely

Dr Steven Mercer
CEO, Tissue Therapies Limited

1740020v4

Tissue Therapies Limited ABN 45 101 955 088 www.tissuetherapies.com
6th Floor, Institute of Health & Biomedical Innovation
60 Musk Ave
Kelvin Grove QLD 4059 Australia
GPO Box 1596 Brisbane Qld 4001
telephone +61 7 3839 9938 facsimile +61 7 3839 1486

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro[®], a platform technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro[®] has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro[®] platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com